Clinical Trial Update: Flexible-Dose Trial in Early Parkinson's Disease (PD) [Phase 3]

View source ↗

Summary

AbbVie's flexible-dose Phase 3 trial in early Parkinson's disease has completed and posted results (as of 2025-11-21).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Snippet

Sponsor: AbbVie | Conditions: Parkinson Disease | Phase 3 | Status: COMPLETED | Results posted: 2025-11-21